Advertisement

Topics

Fatty Liver Imaging Project ( FLIP ) Patient Pilot Study

2019-04-19 12:44:22 | BioPortfolio

Published on BioPortfolio: 2019-04-19T12:44:22-0400

Clinical Trials [1977 Associated Clinical Trials listed on BioPortfolio]

The Effect of n-3 Polyunsaturated Fatty Acid Supplements in Patients With Non-alcoholic Fatty Liver Disease

The principal purpose of this study is to determine whether increased intakes of n-3 polyunsaturated (omega-3) fatty acids will reduce the amount of fat stored in the liver in patients wit...

The Effect of Combination Therapy Amino Acid L-CARNITINE and Magnesium on Fatty Liver

L-carnitine is an amino acid that is naturally produced in the liver and kidneys, it is involved in transporting fatty acids across the mitochondrial membrane, it could be an important com...

Non Alcoholic Fatty Liver Disease Influence of Statin Therapy

Aim: 1. To determine the prevalence of fatty liver in a cohort of patients hospitalized with chest pain in the Cardiology department. 2. To assess the effect of statins on...

Genetic Studies of Non-Alcoholic Fatty Liver Disease

Background: - Non-alcoholic fatty liver disease is the most common form of liver disease in the United States. It includes many conditions. Researchers want to study fatty liver disease b...

Early Detection of Advanced Fatty Liver Disease

Non-alcoholic fatty liver disease is the most common cause of chronic liver disease in the western world, affecting one in every three subjects. The investigators hypothesize that a patie...

PubMed Articles [5851 Associated PubMed Articles listed on BioPortfolio]

Sarcopenic obesity in fatty liver.

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steato hepatitis have an increasing prevalence among liver diseases. Overweight and obesity are frequently associated conditions in patients w...

Nonalcoholic Fatty Liver Disease.

Nonalcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease. Most cases are diagnosed incidentally in the primary care or hospital setting on the basis of elevated liver enz...

A community-based study on the application of fatty liver index in screening subjects with nonalcoholic fatty liver disease.

Nonalcoholic fatty liver disease (NAFLD) is now a global liver disease. The fatty liver index (FLI), which is calculated by the equation comprising waist circumference, body mass index (BMI), triglyce...

CXCR6 deficiency ameliorates ischemia-reperfusion injury by reducing the recruitment and cytokine production of hepatic NKT cells in a mouse model of non-alcoholic fatty liver disease.

Fatty liver is used for transplantation due to organ shortage, but prone to cause complications like ischemia-reperfusion injury (IRI). NKT cells as a bridge between innate and adaptive immunity were ...

MR Imaging: A Personalized approach to understanding fatty liver disease.

To assess information retention by parents/caretakers regarding nonalcoholic fatty liver disease (NAFLD) utilizing the actual image of their child's affected liver.

Medical and Biotech [MESH] Definitions

Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS.

Lipid infiltration of the hepatic parenchymal cells that is due to ALCOHOL ABUSE. The fatty changes in the alcoholic fatty liver may be reversible, depending on the amounts of TRIGLYCERIDES accumulated.

Fatty liver finding without excessive ALCOHOL CONSUMPTION.

A perilipin that functions in LIPOGENESIS; LIPOLYSIS; and fatty acid oxidation in BROWN ADIPOSE TISSUE; heart, liver, and skeletal muscle. It recruits MITOCHONDRIA to the surface of LIPID DROPLETS where it functions in both the storage of fatty acids as TRIGLYCERIDES, and their release for mitochondrial fatty acid oxidation in response to metabolic needs.

Liver diseases associated with ALCOHOLISM. It usually refers to the coexistence of two or more subentities, i.e., ALCOHOLIC FATTY LIVER; ALCOHOLIC HEPATITIS; and ALCOHOLIC CIRRHOSIS.

More From BioPortfolio on "Fatty Liver Imaging Project ( FLIP ) Patient Pilot Study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial